Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Accounts Payables (2023 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Accounts Payables for 5 consecutive years, with $7.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Accounts Payables changed N/A to $7.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $7.2 million, a N/A change, with the full-year FY2023 number at $8.0 million, changed N/A from a year prior.
  • Accounts Payables was $7.2 million for Q3 2024 at Actinium Pharmaceuticals, down from $9.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $9.2 million in Q2 2024 to a low of $7.2 million in Q3 2024.